HOUSTON, Texas and VANCOUVER, BC, March 26, 2021 /CNW/ – ESSA Pharma Inc. (“ESSA” or the “Enterprise”) (Nasdaq: EPIX), a clinical-phase pharmaceutical enterprise focused on building novel therapies for the therapy of prostate cancer, right now introduced that Ari Brettman, M.D., has stepped down from ESSA’s Board of Administrators, which he has been a member of since 2019. Dr. Brettman is a Controlling Director of Blackstone’s Lifestyle Science Team and will be assuming much more duties in this position.
“We are extremely grateful to Dr. Brettman for his strong leadership and useful insights as a member of the Board of Directors,” said Richard M. Glickman, Chairman of ESSA’s Board of Administrators. “On behalf of the total Board and Govt Management Workforce, I would like to thank Dr. Brettman for his contributions and ongoing aid, and we desire him good results in his long term endeavors.”
“It has been an honor to provide on ESSA’s Board and witness the Company’s tremendous advancement in excess of the past number of years,” mentioned Dr. Brettman. “ESSA’s passionate and skilled management crew positions the Firm for ongoing good results and I seem forward to subsequent ESSA’s development and the medical improvement of the guide products prospect, EPI-7386, which has the possible to change the therapy paradigm for prostate most cancers.”
About ESSA Pharma Inc.
ESSA is a clinical-phase pharmaceutical firm focused on producing novel and proprietary therapies for the treatment method of sufferers suffering from prostate most cancers. For much more facts, remember to take a look at www.essapharma.com and observe us on Twitter under @ESSAPharma.
Forward-Seeking Statement Disclaimer
This launch consists of particular information which, as introduced, constitutes “forward-searching information” within just the which means of the Personal Securities Litigation Reform Act of 1995 and/or relevant Canadian securities legal guidelines. Ahead-seeking data requires statements that relate to potential events and frequently addresses anticipated upcoming company and money efficiency, that contains phrases these kinds of as “foresee”, “imagine”, “prepare”, “estimate”, “count on”, and “intend”, statements that an action or occasion “may”, “may”, “could”, “ought to”, or “will” be taken or happen, or other related expressions and contains, but is not minimal to, statements concerning the Company’s positioning for achievement and progress, EPI-7386’s possible to completely transform the treatment method paradigm for prostate cancer and other statements bordering the Firm’s scientific analysis of EPI-7386.
Ahead-looking statements and details are matter to several recognised and unfamiliar hazards and uncertainties, quite a few of which are further than the capacity of ESSA to command or forecast, and which may result in ESSA’s genuine outcomes, performance or achievements to be materially different from those people expressed or implied therefore. These kinds of statements reflect ESSA’s present sights with respect to potential situations, are issue to hazards and uncertainties and are necessarily dependent on a range of estimates and assumptions that, although regarded as reasonable by ESSA as of the date of this kind of statements, are inherently subject to substantial health-related, scientific, small business, economic, competitive, political and social uncertainties and contingencies. In making forward hunting statements, ESSA may make a variety of material assumptions, like but not minimal to (i) the precision of ESSA’s monetary projections (ii) getting favourable final results of clinical trials (iii) acquiring essential regulatory approvals and (iv) general enterprise, sector and financial ailments.
Ahead-hunting facts is designed based on assumptions about this kind of pitfalls, uncertainties and other aspects established out herein and in ESSA’s Yearly Report on Variety 10-K dated December 15, 2021 below the heading “Risk Factors”, a duplicate of which is out there on ESSA’s profile on EDGAR at www.sec.gov, and as if not disclosed from time to time on ESSA’s SEDAR profile www.sedar.com. Ahead-seeking statements are designed primarily based on management’s beliefs, estimates and viewpoints on the date that statements are designed and ESSA undertakes no obligation to update forward-hunting statements if these beliefs, estimates and views or other situation ought to adjust, other than as might be expected by applicable Canadian and United States securities guidelines. Visitors are cautioned from attributing undue certainty to forward-on the lookout statements.
Look at unique information:https://www.prnewswire.com/news-releases/essa-announces-modify-to-its-board-of-administrators-301256925.html
Supply ESSA Pharma Inc